Heron Therapeutics (HRTX) Other financing activities (2010 - 2025)
Heron Therapeutics' (HRTX) quarterly Other financing activities came in at $266000.0 in Q4 2025, down 42.42% YoY from $462000.0 in Q4 2024, and down 42.42% on a QoQ basis from $462000.0 in Q4 2024.
Heron Therapeutics (HRTX) Other financing activities (2010 - 2025) Analysis & Trends
Heron Therapeutics (HRTX) has 16 years of Other financing activities data on file, last reported at $266000.0 in Q4 2025.
- Quarterly Other financing activities fell 42.42% year-over-year to $266000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $728000.0 (up 402.07% YoY) and the FY2025 annual result came in at $853000.0, up 33.91% from the prior year.
- Other financing activities slipped to $266000.0 in Q4 2025, from $462000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $29.1 million in Q3 2023 to a low of -$29.8 million in Q4 2023.
- A 5-year average of $354500.0 and a median of $628000.0 in 2021 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2023 — Other financing activities plunged 4527.68% — and 2024, when it surged 101.55%.
- Tracing HRTX's Other financing activities over 5 years: stood at $610000.0 in 2021, then increased by 10.16% to $672000.0 in 2022, then sank by 4527.68% to -$29.8 million in 2023, then surged by 101.55% to $462000.0 in 2024, then tumbled by 42.42% to $266000.0 in 2025.
- The last three Other financing activities figures came in at $266000.0 (Q4 2025), $462000.0 (Q4 2024), and -$29.8 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 266,000.00 |
| Dec 31, 2025 | 266,000.00 |
| Dec 31, 2024 | 462,000.00 |
| Dec 31, 2024 | 462,000.00 |
| Dec 31, 2023 | -29.75 Mn |
| Dec 31, 2023 | -29.75 Mn |
| Sep 30, 2023 | 29.05 Mn |
| Sep 30, 2023 | 29.05 Mn |
| Dec 31, 2022 | 672,000.00 |
| Dec 31, 2022 | 672,000.00 |
| Dec 31, 2021 | 610,000.00 |
| Dec 31, 2021 | 610,000.00 |
| Jun 30, 2021 | 646,000.00 |
| Jun 30, 2021 | 646,000.00 |
| Mar 31, 2021 | 883,000.00 |
| Mar 31, 2021 | 883,000.00 |
| Dec 31, 2020 | 810,000.00 |
| Dec 31, 2020 | 810,000.00 |
| Jun 30, 2020 | 1.00 Mn |
| Jun 30, 2020 | 1.00 Mn |